Recent advances in bone-targeted therapies of metastatic prostate cancer
about
Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?Metastatic tumors to the jaws and mouth.The αvβ6 integrin is transferred intercellularly via exosomesThe systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer.Expression of the IL-11 Gene in Metastatic Cells Is Supported by Runx2-Smad and Runx2-cJun Complexes Induced by TGFβ1Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer.Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models.Tumor Cell-Derived Exosomes from the Prostate Cancer Cell Line TRAMP-C1 Impair Osteoclast Formation and Differentiation.The cast of clasts: catabolism and vascular invasion during bone growth, repair, and disease by osteoclasts, chondroclasts, and septoclasts.Thrombospondin-2 promotes prostate cancer bone metastasis by the up-regulation of matrix metalloproteinase-2 through down-regulating miR-376c expression.Sphingosine-1-phosphate suppresses chondrosarcoma metastasis by upregulation of tissue inhibitor of metalloproteinase 3 through suppressing miR-101 expression.MicroRNA-30a functions as tumor suppressor and inhibits the proliferation and invasion of prostate cancer cells by down-regulation of SIX1.c-Src, Insulin-Like Growth Factor I Receptor, G-Protein-Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes.Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment.γ-Oryzanol reduces caveolin-1 and PCGEM1 expression, markers of aggressiveness in prostate cancer cell lines.Matrix metalloproteinases and epileptogenesis.Sweet Strategies in Prostate Cancer Biomarker Research: Focus on a Prostate Specific Antigen
P2860
Q27331671-F0F0D4E1-560D-4601-AD18-5D00ACA97602Q28087676-D611328B-93DE-4E61-939C-93590F779E08Q34577367-6CA82A56-812F-4010-A1DA-0F113098A43CQ35103855-6EAEAFDB-222C-4A2B-A608-80BF66E45475Q35181099-455546F3-994C-49C5-BA0D-F78A31A09C80Q35889495-45265240-A86B-413D-92A3-582E3D1E0505Q36009814-7A61305D-2CBA-41EB-834A-232B62237306Q36126224-B8A7A011-3C38-4CB0-903A-35340CC1F90BQ36188851-EC6E6712-FD7A-4DD6-8FB6-E512A38649E4Q37017831-E6788B50-8DB4-459B-AD8A-CFC65227F3F6Q37604954-A531A1BB-072C-4ED7-9A86-CA2189D6C01CQ38663477-B654FCC2-0C07-4BDB-9277-D13E7BD8B6D1Q38675837-4F4D2E0A-49AB-410F-B202-F00690DA5595Q38768131-7B693CCB-FFB4-4C8D-AC07-ED118CFECE85Q38790667-51C84FE7-0DFD-41AB-89A6-9BA618AD36FAQ38916726-93A65176-7A23-440C-B23F-5E0B7AB4F571Q42078040-526B4D16-6C33-4012-9AD2-C305851EF6BCQ59207012-134A09DD-260B-4915-B1FA-4F0ED8B5D0D0
P2860
Recent advances in bone-targeted therapies of metastatic prostate cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Recent advances in bone-targeted therapies of metastatic prostate cancer
@ast
Recent advances in bone-targeted therapies of metastatic prostate cancer
@en
type
label
Recent advances in bone-targeted therapies of metastatic prostate cancer
@ast
Recent advances in bone-targeted therapies of metastatic prostate cancer
@en
prefLabel
Recent advances in bone-targeted therapies of metastatic prostate cancer
@ast
Recent advances in bone-targeted therapies of metastatic prostate cancer
@en
P2093
P2860
P50
P1476
Recent advances in bone-targeted therapies of metastatic prostate cancer
@en
P2093
Evan T Keller
Guangchun He
Jill M Keller
Junwen Liu
Shigang Tang
Xiaoning Peng
Zhiyong Gao
P2860
P304
P356
10.1016/J.CTRV.2014.04.003
P577
2014-04-16T00:00:00Z